APA (7th ed.) Citation

A, B., FE, N., P, l. C., S, S., A, H., E, T., . . . C, M. (2026). Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX). Leukemia, 40(2), 410. https://doi.org/10.1038/s41375-025-02859-1

Chicago Style (17th ed.) Citation

A, Burchert, et al. "Randomized Phase 3 Trial of Ropeginterferon Alfa-2b Versus Surveillance After Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia (ENDURE/CML-IX)." Leukemia 40, no. 2 (2026): 410. https://doi.org/10.1038/s41375-025-02859-1.

MLA (9th ed.) Citation

A, Burchert, et al. "Randomized Phase 3 Trial of Ropeginterferon Alfa-2b Versus Surveillance After Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia (ENDURE/CML-IX)." Leukemia, vol. 40, no. 2, 2026, p. 410, https://doi.org/10.1038/s41375-025-02859-1.